Free Newsletter
U.S. to cancel half of CSL's H1N1 vax order
Free newsletter via e-mail
Tools
The U.S. government wants less than half of the swine flu vaccine it originally sought from CSL and is joining countries such as France and Germany in canceling orders amid waning public concern about the influenza pandemic. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: